Who
Catherine Coste
Director
Company insider
Files Form 4 as: Director, BioLife Solutions; Director and Other, Biomerica; Director, Renalytix; Director, Minerva Surgical.
In numbers
- Trades disclosed
- 14
- Buys
- 2
- Sells
- 0
- Bought
- $56K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 26 Oct 2020
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code D | —13,871 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —8,170 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —8,170 | filing |
| 18 Mar 2025filed 20 Mar 2025 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —5,701 | filing |
| 13 Dec 2024filed 17 Dec 2024 | BMRA BiomericaDiagnostics & Labs | SEC FORM 4 Code A | $26K85,000 at $0.31 | filing |
| 13 Dec 2023filed 14 Dec 2023 | BMRA Biomericaoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —75,000 | filing |
| 20 Nov 2023filed 22 Nov 2023 | Renalytixoption or derivative | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 6 Jul 2023filed 7 Jul 2023 | Renalytixoption or derivative | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 20 Apr 2023filed 11 Dec 2023 | BMRA Biomericaoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —32,000 | filing |
| 26 Jan 2023filed 30 Jan 2023 | BMRA BiomericaDiagnostics & Labs | SEC FORM 4 Bought | $6,4822,190 at $2.96 | filing |
| 10 Jun 2022filed 14 Jun 2022 | Minerva Surgical | SEC FORM 4 Code A | $120K49,792 at $2.41 | filing |
| 9 Dec 2021filed 10 Dec 2021 | BMRA Biomericaoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 | filing |
| 10 Dec 2020filed 11 Dec 2020 | BMRA Biomericaoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —20,000 | filing |
| 26 Oct 2020filed 27 Oct 2020 | BMRA BiomericaDiagnostics & Labs | SEC FORM 4 Bought | $50K9,100 at $5.45 | filing |
News
Contrasting Biomerica (NASDAQ:BMRA) and Envoy Medical (NASDAQ:COCH)BMRA · themarketsdaily.com · 19 Oct 2026Financial Comparison: TerrAscend (OTCMKTS:TSNDF) versus Biomerica (NASDAQ:BMRA)BMRA · dailypolitical.com · 18 Oct 2026Biomerica Reports $1.265 Million in Fiscal First-Quarter Sales and $1.232 Million LossBMRA · econotimes.com · 17 Oct 2026
0 headlines in the last 90 days name Catherine Coste; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.